AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02388048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib + ofatumumab
Study NCT01025791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Study NCT01325298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UV-X Light
Description: UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
Study NCT01768793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Parents As Teachers (PAT)
Description: Participants will receive visits by Parent Educators, who will deliver the standard PAT curriculum. Participants will receive 28 total visits over the course of approximately 2 years.
Study NCT02437123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Cedar Project mHealth intervention
Study NCT01768793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents As Teachers Plus (PAT+)
Description: Participants will receive the standard PAT curriculum, plus lifestyle intervention focusing on healthy diet and exercise, through 28 home visits over the course of approximately 2 years.
Study NCT03948295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid Challenge
Description: After fasting for 10 hours, all participants will undergo a lipid challenge with Calogen. Calogen is a commercially available liquid high-energy long chain triglyceride fat emulsion used to fortify foods. Calogen provides 50 grams of long chain triglycerides per 100 mL. Participants must avoid physical activity during the 6 hour study period to avoid changes in metabolism that could affect the results of the study.
Study NCT01325298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
Study NCT03445104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Huperzine A
Description: During one of the two experimental sessions, participants will be given huperzine A.
Study NCT03445104 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During one of the two experimental sessions, participants will be given a placebo.
Study NCT02927431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin 15 mg FBE
Description: This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion to provide a dose of 15 mg FBE.
Study NCT02927431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin 50 mg FBE
Description: This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion.
Study NCT04267926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mg MitoQ
Description: a third of subject will receive 20mg of oral MitoQ
Study NCT04267926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will receive Placebo
Study NCT03352466 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioThrax
Description: Commercially available anthrax vaccine
Study NCT03352466 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT04267926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40mg of MitoQ
Description: a third of subjects will receive 40mg of MitoQ
Study NCT02927431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.
Study NCT02927431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg
Description: Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.
Study NCT02927431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir 75 mg
Description: Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.
Study NCT01385215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluzone
Description: 0.5 ml/15 micrograms
Study NCT01385215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluzone
Description: 0.5 ml/60 micrograms
Study NCT02602496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruits and Vegetables
Description: 5 servings of fruits or vegetables
Study NCT02602496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Grain
Description: 3 servings of whole grain
Study NCT03256240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: side-to-side functional end anastomosis
Description: type of anastomosis
Study NCT03256240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kono-S analstomosis
Description: antimesenteric anastomosis
Study NCT04090528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP
Description: pTVG-HP is a plasmid DNA, produced in E. coli, that encodes the complementary deoxyribonucleic acid (cDNA) for human prostatic acid phosphatase (PAP).
Study NCT04090528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-AR
Description: pTVG-AR is a plasmid DNA
Study NCT04090528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
Study NCT03808987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child-Parent Psychotherapy (CPP)
Description: Child-Parent Psychotherapy (CPP) focuses on parent-infant relationships, increases efficacy for improved mother-child relationships, more sensitive parenting, healthier child development, and maltreatment prevention. A primary goal is to strengthen the parent-child relationship to improve family functioning and child security of attachment. Through respect, empathic concern, and positive regard, the therapeutic relationship provides mothers with corrective emotional experiences, through which they are able to differentiate current from past relationships, form positive internal representations of themselves and of themselves in relationship to others, particularly their children. Parents are encouraged to process their experiences of trauma and restore parental roles as protective shields, improve affective regulation capacities, enhance understanding of the meaning of behavior, acknowledge the impact of trauma, and support children in a more positive developmental trajectory.
Study NCT03808987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) home visitation
Description: Community Health Worker (CHW) home visitation includes assistance with concrete support needs, such as transportation to medical appointments, referrals for food, housing, and employment services, and attention to developmental needs of young children.
Study NCT03372733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: control olive oil (COO)
Description: 2 capsules, 2 times a day after meals in a total of 4 capsules a day
Study NCT03372733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palmitoleate-rich oil (PLO)
Description: 2 capsules, 2 times a day after meals in a total of 4 capsules a day
Study NCT02347995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein
Description: This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein after each training session.
Study NCT02347995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage after each training session.
Study NCT02602496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 3 servings of refined grain
Study NCT03639298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intendu
Description: intensive training with Motion Based Cognitive Video Games Software
Study NCT01660698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: maltodextrin powder
Study NCT01660698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: probiotic blended in maltodextrin powder
Study NCT01053221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid
Description: Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
Study NCT01053221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care: CNI and MPA
Description: Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
Study NCT02246660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.~OR~The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
Study NCT02246660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken orally for 6 months.
Study NCT03018704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: anticonvulsant medication. The medication was dosed twice per day with a starting dose of 25 mg, increasing the dose as tolerated to 200mg daily in divided doses. Patient were titrated to the highest dose tolerable.
Study NCT03018704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive medication. the doses of placebo were titrated the same as the active intervention.
Study NCT02397785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ApexM
Description: Subjects will apply conductive gel, insert the device to a minimum depth of 4 inches, and inflate until comfortably snug. The intensity is set exclusively by the physician to a tolerated sensory level, avoiding muscle contraction. At the target amplitude, patients will feel a non-painful fluttering or tapping sensation, Subjects will perform this for 6 sessions per week at 12 minutes per session for an additional 12 weeks. At each follow-up visit, investigators will re-evaluate the stimulation level and adjust to avoid muscle contraction.
Study NCT02397785 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Identical to ApexM but will not deliver any electrical stimulation
Study NCT01110434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate (200 mg daily)
Study NCT01110434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (daily)
Study NCT03957720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMPS
Description: Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
Study NCT03957720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillamine
Description: Dosage Form: Penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years;
Study NCT03957720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMSA
Description: Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
Study NCT00359606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoro-2-Deoxycytidine (FdCyd)
Description: Given PO and IV
Study NCT00359606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study NCT00359606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative Studies
Study NCT00359606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine (THU)
Description: Given PO and IV
Study NCT02915315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: salt
Description: The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day). During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration. To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. All foods are cooked without salt. Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
Study NCT00175812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid (ATRA)
Description: All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14
Study NCT00175812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: Valproic acid, highest dose without side effects from day 3 until progression
Study NCT00175812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophyllin
Description: Theophyllin, targetted serum level 50-100 from day 3 until progression
Study NCT02285270 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FDG PET/CT
Description: PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.
Study NCT02866942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Live attenuated influenza vaccine (LAIV)
Study NCT06389890 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreatic resection procedure
Description: Pancreatic resection procedure
Study NCT02458924 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Niacin skin test
Description: Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.
Study NCT03513692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fill-Up composite resin
Description: 2 arm study comparing restoration of a tooth with either FillUp composite or conventional composite
Study NCT03801148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg dexlansoprazole capsules manufactured at TOB
Description: Dexlansoprazole delayed-release capsules.
Study NCT04666558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise & Nutrition
Description: App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking.
Study NCT04666558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise & Nutrition
Description: App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking. Additional one-one-one exercise and nutrition support is provided too.
Study NCT00586040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tissue bonding
Description: application of rose bengal and treatment with green light
Study NCT00586040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sutures
Description: interrupted superficial sutures
Study NCT00898638 — intervention group
Intervention type: OTHER
Intervention: biologic sample preservation procedure
Study NCT01049204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Maraviroc 150 mg twice daily for 24 weeks
Study NCT00898638 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Study NCT01449812 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix+Hib™
Description: Intramuscular, one dose
Study NCT01449812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix+Hib™
Description: Intramuscular, one dose
Study NCT01449812 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliorix™
Description: Intramuscular, one dose
Study NCT01449812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliorix™
Description: Intramuscular, one dose
Study NCT04622319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle
Study NCT04622319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-DM1
Description: Administered initially as an intravenous (IV) infusion at a dose of 3.6 mg/kg on Day 1 of each 21-day cycle
Study NCT04310007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study NCT04310007 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study NCT04310007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT01049204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo twice daily for 24 weeks
Study NCT05066152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (ATCC 53103)
Description: One probiotic drop contained a formulation of 1x109 Cfu Lactobacillus rhamnosus GG (LGG; ATCC 53103)
Study NCT05066152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Carrier material of probiotic product, not containing bacterial strain, similar appearance as the probiotic
Study NCT03490292 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab combined with Chemoradiation
Description: Co-administration of avelumab with chemoradiation in pre-operative period.
Study NCT03490292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Weekly Carboplatin (AUC2) \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
Study NCT03490292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Weekly paclitaxel \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
Study NCT03490292 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy \[23 fractions, M-F, estimated completion day 35\]
Study NCT03101488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN035
Description: KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.